A practical reference on secretagogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-13. Anything still debated is marked as such rather than presented as settled.
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽，含非天然氨基酸残基 |
| 分子量 | 711.85 g/mol | 理论值，盐形式可能略有差异 |
| 外观 | 白色至类白色粉末 | 冻干粉常见 |
| 溶解性 | 易溶于水 | 也可溶于部分极性有机溶剂 |
| 储存条件 | -20°C，干燥避光 | 长期保存通常推荐 |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
=== Late onset form === The Late-onset (LOPD) form differs from the infantile-onset principally in the relative lack of cardiac involvement. The onset has a slower progression and can present at any decade of life. Cardiac involvement may occur but is milder than in the infantile form. Skeletal involvement is more prominent with a predilection for the lower limbs. Late-onset features include impaired cough, recurrent chest infections, hypotonia, progressive muscle weakness, delayed motor milestones, difficulty swallowing or chewing, and reduced vital capacity. Variability in the age of onset, severity, and symptoms, between those as genetically similar as identical twins, indicates that there may be epigenetic - or secondary factors - influencing disease presentation. Prognosis depends on the age of onset of symptoms with a better prognosis being associated with later onset disease.
In 2004, the US decided to grant Major non-NATO ally (MNNA) status to Pakistan. The US extended the MNNA strategic working relationship to India but the offer was turned down. After the September 11 attacks against the US in 2001, President George W. Bush collaborated closely with India in controlling and policing the strategically critical Indian Ocean sea lanes from the Suez Canal to Singapore.
== Prognosis == AMC is considered non-progressive, so with proper medical treatment things can improve. The joint contractures will not get worse than they are at the time of birth. There is no way to resolve or cure AMC completely but with proper treatment most children make significant improvements in their range of motion and ability to move their limbs, which enables them to carry out daily activities and live relatively normal lives. Therapeutic interventions that are cornerstones in the treatment of AMC include: stretching and range of motion exercises, physical, occupational and speech therapy, splinting and serial casting. Surgical intervention may also improve joint mobility and function. Other positive prognostic factors for independent walking are active hips and knees, hip flexion contractures of less than 20 degrees and knee flexion contractures of less than 15 degrees without severe scoliosis.
Subsequent industry developments have included the involvement of major tobacco companies in the e-cigarette market through subsidiaries and acquisitions; for example, British American Tobacco's U.S. unit Reynolds American markets Vuse products, and in 2023 Altria acquired NJOY's e-vapor product portfolio. In parallel with regulatory scrutiny and industry consolidation, e-cigarette manufacturers have faced significant product liability and consumer protection litigation. In April 2023, Juul Labs agreed to pay $462 million to settle claims brought by six U.S. states and the District of Columbia alleging unlawful marketing of its products to minors. Public safety concerns related to lithium ion batteries have also extended beyond consumer use to storage, disposal, and waste handling. Public safety authorities have warned about fire risks associated with lithium ion batteries in disposable e-cigarettes during storage, disposal and waste handling. Ahead of the United Kingdom's disposable vape ban taking effect in June 2025, the Local Government Association cautioned that lithium batteries inside disposable vapes could pose a fire and risk-to-life hazard if not stored correctly. In the UK, these concerns have been reflected in government and media reporting on waste-related fires. In 2025, reporting linked discarded single use vapes to fires in waste collection vehicles and recycling facilities, citing warning from the Department for Environment, Food & Rural Affairs and estimates of more than 1,200 battery-related fires at waste sites in 2023.
Sources: en.wikipedia.org
=== Content protection === DisplayPort 1.0 includes optional DPCP (DisplayPort Content Protection) from Philips, which uses 128-bit AES encryption. It also features full authentication and session key establishment. Each encryption session is independent, and it has an independent revocation system. This portion of the standard is licensed separately. It also adds the ability to verify the proximity of the receiver and transmitter, a technique intended to ensure users are not bypassing the content protection system to send data out to distant, unauthorized users. DisplayPort 1.1 added optional implementation of industry-standard 56-bit HDCP (High-bandwidth Digital Content Protection) revision 1.3, which requires separate licensing from the Digital Content Protection LLC. DisplayPort 1.3 added support for HDCP 2.2, which is also used by HDMI 2.0.
These companies include Sentilus, a clinical diagnostics company that was acquired by Immucor in 2014, Phase Bio Pharmaceuticals—a drug delivery company—that had an IPO on NASDAQ in 2018, Isolere Bio—that uses ELPs to purify complex biologics without chromatography—that was acquired by Donaldson in 2023, and inSoma Bio, that has focused on commercializing injectable biomaterials developed in his laboratory for tissue reconstruction.
The high degree of interconnectivity in monoliths confers an advantage seen in the low backpressures and readily achievable high flow rates. Monoliths are ideally suited for large molecules; although the purification of larger molecules can be very time-consuming. As mentioned previously, particle sizes are decreasing in an attempt to achieve higher resolution and faster separations, which led to higher backpressures. When the smaller particle sizes are used to separate biomolecules, backpressures increase further because of the large molecule size. In monoliths, where backpressures are low and channel sizes are large, small molecule separations are less efficient. This is demonstrated by the dynamic binding capacities, a measure of how much sample can bind to the surface of the stationary phase. Dynamic binding capacities of monoliths for large molecules can be an order of ten times greater than that for particulate packings. Monoliths exhibit no shear forces or eddying effects. High interconnectivity of the mesopores allows for multiple avenues of convective flow through the column. Mass transport of solutes through the column is relatively unaffected by flow rate. This is completely at odds to traditional particulate packings, whereby eddy effects and shear forces contribute greatly to the loss of resolution and capacity, as seen in the vanDeemter curve. Monoliths can, however, suffer from a different flow disadvantage: wall effects. Silica monoliths, especially, have a tendency to pull away from the sides of their column encasing.
Sources: en.wikipedia.org
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。
生长激素释放激素通过其专用受体起作用，而 ipamorelin 主要作用于胃饥饿素受体。两者可影响生长激素释放，但信号通路和下游效应并不相同。
研究多集中在生长激素释放的急性调节、受体选择性以及不同给药方式下的药代动力学。临床终点研究数量有限，长期结局尚不明确。
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.